Virtual | May 9, 2022 | 1-5 pm ET
NINDS is a member of the Muscular Dystrophy Coordinating Committee (MDCC), a Federal Advisory Committee including NIH institutes, other Federal agencies, and patient advocates. The MDCC identifies the many challenges confronting people with muscular dystrophy and their families and coordinates efforts to address them.
Agenda
| Time | Presentation |
|---|---|
| 1:00 – 1:10 |
Introductions and general information Glen Nuckolls, National Institute of Neurological Disorders and Stroke (NINDS/NIH), MDCC Designated Federal Official |
| 1:10 – 1:40 |
Chair Presentation Diana Bianchi, Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD/NIH), MDCC Chair |
| 1:40-2:00 |
Science Advances Supported by the Centers for Disease Control and Prevention (CDC) Natalie Street, CDC |
| 2:00 – 2:45 |
New Member Presentations Denise Myler, Idaho Caregivers Alliance and the Idaho State Independent Living Council Eric Wang, Myotonic Dystrophy Foundation and Center for Neurogenetics, Univ Florida Chris Anselmo, Muscular Dystrophy Association |
| 2:45-3:00 | Break |
| 3:00 – 4:55 |
“Repurposing Approved Drugs and Previously Deprioritized Compounds” Session Introduction Repurposing of Drugs for the Treatment of Duchenne Muscular Dystrophy Drug Repurposing Projects by the NCATS Therapeutics Development Branch Creating Value through Clinical Repurposing Repurposing in Muscular Dystrophy: Lessons from FDA/NCATS CURE ID and the CURE Drug Repurposing Collaboratory (CDRC) |
| 4:55 - 5:00 | Closing Remarks Diana Bianchi, NICHD/NIH |
| 5:00 | Adjourn |